Spring Bank Pharmaceuticals

OverviewSuggest Edit

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using a proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states.
Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. It has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. 

TypePublic
Founded2002
HQHopkinton, US
Websitespringbankpharm.com

Latest Updates

Employees (est.) (Feb 2019)29(+39%)
Share Price (Oct 2019)$3.2 (+3%)

Key People/Management at Spring Bank Pharmaceuticals

Martin Driscoll

Martin Driscoll

Chairman, President and Chief Executive Officer
Nezam Afdhal

Nezam Afdhal

Chief Medical Officer
Jonathan Freve

Jonathan Freve

Chief Financial Officer, Treasurer
Donald Mitchell

Donald Mitchell

Vice President of Operations & Corporate Development
Kevin Leach

Kevin Leach

Vice President, Nonclinical and Translational Research
Garrett Winslow

Garrett Winslow

General Counsel
Show more

Spring Bank Pharmaceuticals Office Locations

Spring Bank Pharmaceuticals has offices in Hopkinton and Milford
Hopkinton, US (HQ)
86 South St
Milford, US
113 Cedar St
Show all (2)

Spring Bank Pharmaceuticals Financials and Metrics

Spring Bank Pharmaceuticals Revenue

USD

Net income (Q2, 2019)

(4.6m)

EBIT (Q2, 2019)

(9.8m)

Market capitalization (11-Oct-2019)

52.3m

Closing stock price (11-Oct-2019)

3.2

Cash (30-Jun-2019)

10.5m
Spring Bank Pharmaceuticals's current market capitalization is $52.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

5.7m8.2m8.7m

R&D expense

14.0m13.1m19.8m

Operating expense total

19.8m21.3m28.5m

EBIT

(19.4m)(21.3m)(28.5m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

1.2m1.5m1.5m2.0m1.9m2.0m2.2m2.4m2.1m2.8m2.5m

R&D expense

5.6m2.9m2.7m2.5m3.4m3.2m4.0m5.6m5.7m5.6m7.3m

Operating expense total

6.8m4.4m4.2m4.5m5.3m5.2m6.2m8.0m7.7m8.4m9.8m

EBIT

(6.5m)(4.3m)(4.2m)(4.5m)(5.3m)(5.2m)(6.2m)(8.0m)(7.7m)(8.4m)(9.8m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

10.7m23.6m14.7m

Accounts Receivable

57.4m

Inventories

840.0k

Current Assets

25.6m51.1m49.3m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(17.4m)(27.7m)(22.9m)

Depreciation and Amortization

118.0k158.0k288.0k

Inventories

(527.0k)

Accounts Payable

(812.0k)181.0k180.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Net Income

(6.5m)(10.8m)(15.0m)(6.5m)(15.4m)(26.2m)(4.9m)(8.6m)(5.2m)(9.7m)

Depreciation and Amortization

26.0k57.0k87.0k36.0k76.0k115.0k45.0k86.0k83.0k171.0k

Accounts Payable

(840.0k)(564.0k)148.0k519.0k432.0k254.0k(45.0k)(12.0k)106.0k(155.0k)

Cash From Operating Activities

(4.6m)(8.9m)(11.7m)(4.1m)(8.8m)(12.6m)(6.2m)(13.0m)(6.8m)(14.8m)
Show all financial metrics

Spring Bank Pharmaceuticals Online and Social Media Presence

Embed Graph

Spring Bank Pharmaceuticals News and Updates

Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update

HOPKINTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for…

Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update

HOPKINTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results fo…

Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights

Conference Call to be Held at 8:00 am Eastern TimeInarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019

Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development

HOPKINTON, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the appointment of Atif A…

Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present at t…

Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018

HOPKINTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a Research &…
Show more

Spring Bank Pharmaceuticals Blogs

Spring Bank Announces Additional Inarigivir Results at AASLD Conference

*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral

Taylor Feehley, Ph.D.

Taylor Feehley, Ph.D. Donna.Al-Beiro… Mon, 10/29/2018 - 10:48 Taylor Feehley, Ph.D. Chardan

Edward Tenthoff

Edward Tenthoff Donna.Al-Beiro… Thu, 10/11/2018 - 13:28 Edward Tenthoff Piper Jaffray

Maury Raycroft, Ph.D.

Maury Raycroft, Ph.D. Donna.Al-Beiro… Thu, 10/11/2018 - 13:26 Maury Raycroft, Ph.D. Jefferies

Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference

HOPKINTON, Mass. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain ca... The post Spring Bank Pharmaceuticals, Inc. t…

Timothy Clackson, Ph.D.

Timothy Clackson, Ph.D. Donna.Al-Beiro… Fri, 09/14/2018 - 10:28 Member of the Compensation Committee Chair of the Science and Technology Committee Timothy Clackson, Ph.D. Director
Show more

Spring Bank Pharmaceuticals Frequently Asked Questions

  • When was Spring Bank Pharmaceuticals founded?

    Spring Bank Pharmaceuticals was founded in 2002.

  • Who are Spring Bank Pharmaceuticals key executives?

    Spring Bank Pharmaceuticals's key executives are Martin Driscoll, Nezam Afdhal and Jonathan Freve.

  • How many employees does Spring Bank Pharmaceuticals have?

    Spring Bank Pharmaceuticals has 29 employees.

  • Who are Spring Bank Pharmaceuticals competitors?

    Competitors of Spring Bank Pharmaceuticals include Achillion Pharmaceuticals, Oxford Biomedica and ACADIA Pharmaceuticals.

  • Where is Spring Bank Pharmaceuticals headquarters?

    Spring Bank Pharmaceuticals headquarters is located at 86 South St, Hopkinton.

  • Where are Spring Bank Pharmaceuticals offices?

    Spring Bank Pharmaceuticals has offices in Hopkinton and Milford.

  • How many offices does Spring Bank Pharmaceuticals have?

    Spring Bank Pharmaceuticals has 2 offices.